Hydroxamic Acid Lipid Composition for Low-Toxicity Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid compositions used for nucleic acid delivery exhibit toxicity and inefficiency, necessitating a more effective delivery method.
Innovation Solution
A lipid composition comprising specific molar ratios of lipids represented by Formula (1) or its salts, nonionic lipids, and nonionic hydrophilic polymers, with optional zwitterionic lipids, achieving a molar ratio difference of 40<(A)−(B)≤90, where A and B represent the molar percentages of these lipids, enhancing nucleic acid delivery efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipids with amino groups are used for nucleic acid delivery, then delivery efficiency is improved, but toxicity increases
Solution Approach 1:
The patent changes the chemical parameters of the lipid by replacing the traditional amino group with a hydroxamic acid group (—CO—NH—OH). This parameter change allows the lipid to maintain cationic character and nucleic acid binding capability while significantly reducing toxicity. The hydroxamic acid group can coordinate with metal ions to form cationic species that effectively deliver nucleic acids without the harmful effects of traditional amino-based cationic lipids.
Solution Approach 2:
The patent creates a composite lipid structure by combining a hydrophobic alkyl chain portion with a hydroxamic acid functional group. This composite structure enables the lipid to interact with both the lipid bilayer membrane and nucleic acids through coordination chemistry, achieving effective delivery while maintaining biocompatibility. The specific composite formula (1) with defined carbon chain lengths and hydroxamic acid groups optimizes both delivery efficiency and reduced toxicity.
2Productivity
If higher molar ratio of cationic lipid is used, then nucleic acid delivery efficiency is improved, but particle aggregation increases
Solution Approach 1:
The patent changes the charge density parameter by using hydroxamic acid groups instead of amino groups. The hydroxamic acid-based cationic lipid achieves effective nucleic acid complexation at lower molar ratios (5-50 mol%), preventing particle aggregation while maintaining delivery efficiency. The coordination chemistry of hydroxamic acid with metal ions provides controlled cationic character that avoids excessive charge density and subsequent aggregation.
3Reliability
If traditional cationic lipid composition is used, then nucleic acid complexation is achieved, but in vivo delivery performance is insufficient
Solution Approach 1:
The patent changes multiple parameters simultaneously: the functional group (hydroxamic acid instead of amino), the metal ion coordination capability, and the hydrophobic-hydrophilic balance. These parameter changes enable the lipid to form stable nucleic acid complexes in vitro while also providing improved in vivo delivery performance through enhanced biocompatibility, reduced immune recognition, and optimized cellular uptake mechanisms.
Solution Approach 2:
The patent designs a composite lipid-nucleic acid-metal ion complex where the hydroxamic acid lipid (formula 1) coordinates with divalent or trivalent metal ions to form a composite delivery system. This composite structure provides stable nucleic acid complexation while the specific molecular architecture (alkyl chains R1-R8, hydroxamic acid group) enables improved in vivo delivery through controlled release and cellular internalization mechanisms.
Data Source
AI summary
An object of the present invention is to provide a lipid composition making it possible to achieve excellent delivery of nucleic acids. According to the present invention, there is provided a lipid composition containing a lipid represented by Formula (1) or a salt thereof, a nonionic lipid, a lipid having a nonionic hydrophilic polymer structure, and a nucleic acid, in which the lipid composition contains or does not contain a zwitterionic lipid, and in a case where (A) represents a molar ratio in percentage of the lipid represented by Formula (1) or a salt thereof to total lipids constituting the lipid composition and (B) represents a molar ratio in percentage of the zwitterionic lipid to total lipids constituting the lipid composition, (A) and (B) satisfy 40<(A)−(B)≤90.In the formula, X represents —NR1— or —O—, R1 represents a hydrogen atom, a hydrocarbon group, or the like, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R4 and R5, R10 and R5, R5 and R12, R4 and R6, R5 and R6, R6 and R7, R6 and R10, R12 and R7, and R7 and R8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is 1 or more, and c+d is 1 or more.